Indianapolis-based pharmaceutical company Eli Lilly announced Monday that it will sell a generic version of Humalog, its branded insulin product. The generic will cost $137 per vial, or half as much as Humalog. Lilly’s move is seen as a partial concession to lawmakers who have grilled pharma companies about the high cost of life-saving prescription drugs. But the company will keep Humalog at its current price. Why this two-tiered drug strategy?
Click the audio player above to hear the full story.
As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.
Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.
Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.